First reported pediatric case of systemic lupus erythematosus associated with prolactinoma

Arthritis and Rheumatism

Volumn 50, Issue 11, 2004, Pages 3616-3618

  Reuman, Peter D ^a  

^a AKRON CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BROMOCRIPTINE MESILATE; DOUBLE STRANDED DNA; IBUPROFEN; NAPROXEN; PROLACTIN;

ADOLESCENT; AMENORRHEA; ANAMNESIS; ARTHRALGIA; ARTHRITIS; ARTICLE; BRAIN CYST; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; FAMILY HISTORY; FEMALE; GALACTORRHEA; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS DISEASE; INFLAMMATION; LABORATORY TEST; MEDIATOR; MENSTRUAL CYCLE; NEUROSURGERY; PLEURA FLUID; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY;

ADOLESCENT; ARTHRITIS; BROMOCRIPTINE; FEMALE; HORMONE ANTAGONISTS; HUMANS; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; TREATMENT OUTCOME;

EID: 8444229717     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20751     Document Type: Article

References (16)

1. Neill JD, Nagy GM. Prolactin secretion and its control. In: Knobil E, Neill JD, editors. The physiology of reproduction. New York: Raven Press; 1994. p. 1833-60.
2. Yu-Lee LY. Molecular actions of prolactin in the immune system. Proc Soc Exp Biol Med 1997;215:35-52.
3. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996;17:639-69.
4. Walker SE, McMurray RW, Houri JM, Allen SH, Keisler D, Sharp GC, et al. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Ann N Y Acad Sci 1998;840:762-72.
5. Jara LJ, Vera-Lastra O, Miranda JM, Alcala M, Alvarez-Nemegyei J. Prolactin in human systemic lupus erythematosus. Lupus 2001;10:748-56.
6. Funauchi M, Ikoma S, Enomoto H, Sugiyama M, Ohno M, Hamada K, et al. Prolactin modulates the disease activity of systemic lupus erythematosus accompanied by prolactinoma. Clin Exp Rheumatol 1998;16:479-82.
7. Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 2001;10:554-61.
8. Vera-Lastra O, Mendez C, Jara LJ, Cisneros M, Medina G, Ariza R, et al. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus: effect of conventional treatment. J Rheumatol 2003;30:2140-6.
9. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
10. Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev 2002;1:360-4.
11. McMurray RW. Prolactin in murine systemic lupus erythematosus. Lupus 2001;10:742-7.
12. Mendez I, Alcocer-Varela J, Lava-Zavala A, de la Cruz DA, Alarcon-Segovia D, Larrea F. Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin. Lupus 2004;13:45-53.
13. Vidaller A, Guadarrama F, Llorente L, Mendez JB, Larrea F, Villa AR, et al. Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient. J Clin Immunol 1992;12:210-5.
14. Walker SE. Bromocriptine treatment of systemic lupus erythematosus. Lupus 2001;10:762-8.
15. Jara LJ, Irigoyen L, Ortiz MJ, Zazueta B, Bravo G, Espinoza LR. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol 1998;17:110-14.
16. Duntas LH. Prolactinomas in children and adolescents: consequences in adult life. J Pediatr Endocrinol Metab 2001;14:1227-32.